Check out Kristin Yarema & BioCentury on “Creating CAR T therapies that don’t cause cancer"


John Schmid

Audit Committee Chair

Mr. Schmid has more than 30 years of strategic, operational and financial expertise in the life sciences industry. He was the chief financial officer of Auspex Pharmaceuticals through an IPO and eventual acquisition by Teva Pharmaceuticals for $3.5 billion. He was also co-founder and chief financial officer of Trius Therapeutics, which went public in 2010 and was acquired by Cubist Pharmaceuticals for over $700 million in 2013. He also served as chief financial officer of GeneFormatics and Endonetics (acquired by Medtronic). He currently serves on the board of directors at AnaptysBio, Neos Therapeutics, and Xeris Pharmaceuticals. Mr. Schmid holds a B.A. in economics from Wesleyan University and an M.B.A. from the University of San Diego. He is a past president and a past board member of the San Diego Venture Group.